Free Trial

Molina Healthcare (MOH) Financials

Molina Healthcare logo
$225.81 +16.32 (+7.79%)
As of 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Molina Healthcare

Annual Income Statements for Molina Healthcare

This table shows Molina Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
143 52 -512 707 737 673 659 792 1,091 1,179 472
Consolidated Net Income / (Loss)
143 52 -512 707 737 673 659 792 1,091 1,179 472
Net Income / (Loss) Continuing Operations
143 52 -512 707 737 673 659 792 1,091 1,179 472
Total Pre-Tax Income
322 205 -612 999 972 961 875 1,063 1,464 1,589 589
Total Operating Income
387 306 -555 1,131 1,044 1,078 1,020 1,173 1,573 1,707 781
Total Gross Profit
13,985 17,297 2,318 3,389 2,924 3,603 4,067 4,799 5,403 6,222 5,938
Total Revenue
14,178 17,782 19,883 18,890 16,829 19,423 27,771 31,974 34,072 40,650 45,426
Operating Revenue
14,178 17,782 19,883 18,890 16,829 19,423 27,771 31,974 34,072 40,650 45,426
Total Cost of Revenue
193 485 17,565 15,501 13,905 15,820 23,704 27,175 28,669 34,428 39,488
Operating Cost of Revenue
193 485 17,565 15,501 13,905 15,820 23,704 27,175 28,669 34,428 39,488
Total Operating Expenses
13,598 16,991 2,873 2,258 1,880 2,525 3,047 3,626 3,830 4,515 5,157
Selling, General & Admin Expense
1,146 1,393 1,594 1,394 1,302 1,511 2,129 2,369 2,590 2,843 3,099
Depreciation Expense
104 139 137 99 89 88 131 176 171 186 195
Other Operating Expenses / (Income)
12,348 15,459 438 765 489 926 787 873 1,069 1,486 1,863
Total Other Income / (Expense), net
-65 -101 -57 -132 -72 -117 -145 -110 -109 -118 -192
Interest Expense
66 101 118 115 87 102 120 110 109 118 192
Income Tax Expense
179 153 -100 292 235 288 216 271 373 410 117
Basic Earnings per Share
$2.75 $0.93 ($9.07) $11.57 $11.85 $11.40 $11.40 $13.72 $18.91 $20.52 $8.93
Weighted Average Basic Shares Outstanding
52M 55M 56.40M 61.10M 62.20M 59M 57.80M 57.80M 57.70M 57.40M 52.80M
Diluted Earnings per Share
$2.58 $0.92 ($9.07) $10.61 $11.47 $11.23 $11.25 $13.55 $18.77 $20.42 $8.92
Weighted Average Diluted Shares Outstanding
56M 56.20M 56.40M 66.60M 64.20M 59.90M 58.60M 58.50M 58.10M 57.70M 52.90M
Weighted Average Basic & Diluted Shares Outstanding
52M 55.90M 56.40M 61.10M 60.80M 58M 58.40M 57.90M 58.40M 55.50M 51.50M

Quarterly Income Statements for Molina Healthcare

This table shows Molina Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
301 301 326 251 298 255 79 -160 14 60 38
Consolidated Net Income / (Loss)
301 301 326 251 298 255 79 -160 14 60 38
Net Income / (Loss) Continuing Operations
301 301 326 251 298 255 79 -160 14 60 38
Total Pre-Tax Income
399 406 438 346 390 325 88 -214 29 91 53
Total Operating Income
426 434 467 380 433 373 137 -162 83 145 106
Total Gross Profit
1,517 1,512 1,697 1,496 1,668 1,598 1,433 1,239 1,526 1,434 1,363
Total Revenue
9,931 9,880 10,340 10,499 11,147 11,427 11,477 11,375 10,796 10,874 11,082
Operating Revenue
9,931 9,880 10,340 10,499 11,147 11,427 11,477 11,375 10,796 10,874 11,082
Total Cost of Revenue
8,414 8,368 8,643 9,003 9,479 9,829 10,044 10,136 9,270 9,440 9,719
Operating Cost of Revenue
8,414 8,368 8,643 9,003 9,479 9,829 10,044 10,136 9,270 9,440 9,719
Total Operating Expenses
1,091 1,078 1,230 1,115 1,235 1,225 1,296 1,401 1,443 1,289 1,257
Selling, General & Admin Expense
749 734 676 684 774 711 729 835 779 724 710
Depreciation Expense
45 46 47 48 48 58 45 44 39 40 38
Other Operating Expenses / (Income)
297 298 507 383 413 456 522 522 532 525 509
Impairment Charge
- - - - 0.00 0.00 0.00 - 93 0.00 0.00
Total Other Income / (Expense), net
-27 -28 -29 -34 -43 -48 -49 -52 -54 -54 -53
Interest Expense
27 28 29 34 43 48 49 52 54 54 53
Income Tax Expense
98 105 112 95 92 70 9.00 -54 15 31 15
Basic Earnings per Share
$5.21 $5.18 $5.67 $4.46 $5.47 $4.75 $1.51 ($2.80) $0.27 $1.19 $0.74
Weighted Average Basic Shares Outstanding
58.60M 58.60M 57.20M 57.40M 54.20M 54.20M 51.40M 52.80M 52.10M 52.20M 52.20M
Diluted Earnings per Share
$5.17 $5.17 $5.65 $4.43 $5.45 $4.75 $1.51 ($2.79) $0.27 $1.19 $0.73
Weighted Average Diluted Shares Outstanding
58.60M 58.60M 57.20M 57.70M 54.20M 54.20M 51.40M 52.90M 52.10M 52.20M 52.20M
Weighted Average Basic & Diluted Shares Outstanding
58.60M 58.60M 57.20M 55.50M 54.20M 54.20M 51.40M 51.50M 52.10M 52.20M 52.20M

Annual Cash Flow Statements for Molina Healthcare

This table details how cash moves in and out of Molina Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
790 486 378 -364 -418 1,715 283 -458 860 -167 -393
Net Cash From Operating Activities
1,125 673 804 -314 434 1,898 2,119 773 1,662 644 -535
Net Cash From Continuing Operating Activities
1,125 673 804 -314 434 1,898 2,119 773 1,662 644 -535
Net Income / (Loss) Continuing Operations
143 52 -512 707 737 673 659 792 1,091 1,179 472
Consolidated Net Income / (Loss)
143 52 -512 707 737 673 659 792 1,091 1,179 472
Depreciation Expense
126 182 178 127 89 88 131 176 171 186 195
Non-Cash Adjustments To Reconcile Net Income
23 26 931 81 24 72 1,143 311 115 116 47
Changes in Operating Assets and Liabilities, net
803 382 175 -1,229 -416 1,065 186 -506 285 -837 -1,249
Net Cash From Investing Activities
-1,420 -206 -1,062 1,143 -293 -400 -1,653 -790 -744 -464 312
Net Cash From Continuing Investing Activities
-1,420 -206 -1,062 1,143 -293 -400 -1,653 -790 -744 -464 312
Purchase of Property, Plant & Equipment
-132 -176 -86 -30 -57 -74 -77 -91 -84 -100 -101
Acquisitions
-450 -48 - 0.00 0.00 -755 -129 -134 -3.00 -344 -245
Purchase of Investments
-1,929 -1,929 -2,697 -1,444 -2,536 -670 -2,713 -1,913 -1,433 -1,132 -751
Sale and/or Maturity of Investments
1,126 1,966 1,759 2,445 2,302 1,097 1,329 1,398 772 1,111 1,408
Other Investing Activities, net
-35 -19 -38 -18 -2.00 2.00 -63 -50 4.00 1.00 1.00
Net Cash From Financing Activities
1,085 19 636 -1,193 -559 217 -183 -441 -58 -347 -170
Net Cash From Continuing Financing Activities
1,085 19 636 -1,193 -559 217 -183 -441 -58 -347 -170
Repayment of Debt
0.00 0.00 11 -662 -211 -948 -722 33 2.00 -330 -1,071
Repurchase of Common Equity
- 0.00 0.00 -549 -561 -636 -128 -400 0.00 -1,000 -1,000
Issuance of Debt
694 19 625 18 220 1,809 740 0.00 0.00 1,040 1,938
Other Financing Activities, net
- 0.00 0.00 0.00 -7.00 -8.00 -73 -74 -60 -57 -37
Cash Interest Paid
38 66 78 93 78 112 127 108 108 121 181

Quarterly Cash Flow Statements for Molina Healthcare

This table details how cash moves in and out of Molina Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-336 -154 461 -138 214 -363 -268 24 1,073 -328 -475
Net Cash From Operating Activities
214 -219 873 -224 190 -302 -125 -298 1,082 -294 -159
Net Cash From Continuing Operating Activities
214 -219 873 -224 190 -302 -125 -298 1,082 -294 -159
Net Income / (Loss) Continuing Operations
301 301 326 251 298 255 79 -160 14 60 38
Consolidated Net Income / (Loss)
301 301 326 251 298 255 79 -160 14 60 38
Depreciation Expense
45 46 47 48 48 58 45 44 39 40 38
Non-Cash Adjustments To Reconcile Net Income
36 -194 73 -435 27 3.00 -3.00 20 485 -333 26
Changes in Operating Assets and Liabilities, net
-168 -372 427 -88 -183 -618 -246 -202 544 -61 -261
Net Cash From Investing Activities
-488 53 -48 19 -123 128 77 230 11 -30 -309
Net Cash From Continuing Investing Activities
-488 53 -48 19 -123 128 77 230 11 -30 -309
Purchase of Property, Plant & Equipment
-27 -27 -35 -11 -22 -42 -38 1.00 -27 -30 -37
Purchase of Investments
-380 -214 -395 -143 -189 -232 -186 -144 -249 -377 -619
Sale and/or Maturity of Investments
211 295 365 240 331 386 300 391 295 377 348
Other Investing Activities, net
3.00 -1.00 66 -67 2.00 16 1.00 -18 -8.00 - -1.00
Net Cash From Financing Activities
-62 12 -364 67 147 -189 -220 92 -20 -4.00 -7.00
Net Cash From Continuing Financing Activities
-62 12 -364 67 147 -189 -220 92 -20 -4.00 -7.00
Repayment of Debt
-6.00 12 -163 -173 33 -189 -169 -746 -6.00 -4.00 -6.00
Other Financing Activities, net
-56 - -1.00 - -36 - -1.00 - -14 - -1.00

Annual Balance Sheets for Molina Healthcare

This table presents Molina Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
6,576 7,449 8,471 7,154 6,787 9,532 12,209 12,314 14,892 15,630 15,564
Total Current Assets
5,306 5,988 7,511 6,462 5,967 7,876 10,064 10,084 12,542 12,773 12,444
Cash & Equivalents
2,329 2,819 3,186 2,826 2,452 4,154 4,438 4,006 4,848 4,662 4,248
Short-Term Investments
1,801 1,758 2,524 1,681 1,946 1,875 3,202 3,499 4,259 4,325 4,008
Accounts Receivable
597 974 871 1,330 1,406 1,672 2,177 2,302 3,104 3,299 3,533
Prepaid Expenses
192 131 239 149 163 175 247 277 331 487 655
Plant, Property, & Equipment, net
393 454 342 241 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
877 1,007 618 451 820 1,656 2,145 2,230 2,350 2,857 3,120
Long-Term Investments
109 110 119 120 79 136 212 238 261 286 299
Goodwill
519 620 255 190 172 941 1,252 1,390 1,449 1,938 2,195
Noncurrent Deferred & Refundable Income Taxes
18 10 103 117 79 69 106 220 227 207 178
Other Noncurrent Operating Assets
109 127 141 24 490 510 575 382 413 426 448
Total Liabilities & Shareholders' Equity
6,576 7,449 8,471 7,154 6,787 9,532 12,209 12,314 14,892 15,630 15,564
Total Liabilities
5,019 5,800 7,134 5,507 4,827 7,436 9,579 9,350 10,677 11,134 11,495
Total Current Liabilities
3,822 4,570 5,557 4,246 3,269 4,965 7,047 6,855 8,168 7,896 7,372
Accounts Payable
362 385 366 390 502 641 842 889 1,252 1,331 1,093
Current Deferred Revenue
223 315 282 211 249 375 370 359 418 51 66
Other Current Liabilities
2,788 3,398 4,256 3,404 2,518 3,949 5,835 5,607 6,498 6,514 6,213
Total Noncurrent Liabilities
1,197 1,230 1,577 1,261 1,558 2,471 2,532 2,495 2,509 3,238 4,123
Long-Term Debt
962 975 1,318 1,020 1,237 2,127 2,173 2,176 2,180 2,923 3,766
Other Noncurrent Operating Liabilities
37 42 61 44 321 344 359 319 329 315 357
Total Equity & Noncontrolling Interests
1,557 1,649 1,337 1,647 1,960 2,096 2,630 2,964 4,215 4,496 4,069
Total Preferred & Common Equity
1,557 1,649 1,337 1,647 1,960 2,096 2,630 2,964 4,215 4,496 4,069
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,557 1,649 1,337 1,647 1,960 2,096 2,630 2,964 4,215 4,496 4,069
Common Stock
803 841 1,044 643 175 199 236 328 410 462 452
Retained Earnings
758 810 298 1,012 1,781 1,860 2,399 2,796 3,887 4,091 3,602
Accumulated Other Comprehensive Income / (Loss)
-4.00 -2.00 -5.00 -8.00 4.00 37 -5.00 -160 -82 -57 15

Quarterly Balance Sheets for Molina Healthcare

This table presents Molina Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
14,892 15,513 15,185 15,758 15,630 16,386 16,209 15,698 16,391 16,003 15,652
Total Current Assets
12,542 12,668 12,331 12,881 12,773 13,257 13,112 12,552 13,326 12,928 12,514
Cash & Equivalents
4,848 4,513 4,354 4,732 4,662 4,856 4,499 4,221 5,314 4,985 4,479
Short-Term Investments
4,259 4,424 4,347 4,482 4,325 4,438 4,310 4,226 3,937 3,930 4,100
Accounts Receivable
3,104 3,350 3,231 3,259 3,299 3,491 3,865 3,515 3,420 3,485 3,359
Prepaid Expenses
331 381 399 408 487 472 438 590 655 528 576
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
2,350 2,845 2,854 2,877 2,857 3,129 3,097 3,146 3,065 3,075 3,138
Long-Term Investments
261 261 268 289 286 311 291 300 312 313 345
Goodwill
1,449 1,927 1,913 1,923 1,938 2,175 2,168 2,202 2,092 2,082 2,073
Noncurrent Deferred & Refundable Income Taxes
227 228 232 227 207 193 185 179 215 229 267
Other Noncurrent Operating Assets
413 429 441 438 426 450 453 465 446 451 453
Total Liabilities & Shareholders' Equity
14,892 15,513 15,185 15,758 15,630 16,386 16,209 15,698 16,391 16,003 15,652
Total Liabilities
10,677 11,020 10,342 10,988 11,134 12,076 11,606 11,507 12,311 11,832 11,497
Total Current Liabilities
8,168 8,514 7,836 8,337 7,896 8,155 7,876 7,481 8,188 7,700 7,394
Accounts Payable
1,252 1,114 973 1,215 1,331 1,119 1,113 1,124 1,161 1,139 1,183
Current Deferred Revenue
418 328 13 364 51 369 57 73 401 69 82
Other Current Liabilities
6,498 7,072 6,850 6,758 6,514 6,667 6,706 6,284 6,626 6,492 6,129
Total Noncurrent Liabilities
2,509 2,506 2,506 2,651 3,238 3,921 3,730 4,026 4,123 4,132 4,103
Long-Term Debt
2,180 2,180 2,181 2,332 2,923 3,574 3,375 3,664 3,767 3,769 3,771
Other Noncurrent Operating Liabilities
329 326 325 319 315 347 355 362 356 363 332
Total Equity & Noncontrolling Interests
4,215 4,493 4,843 4,770 4,496 4,310 4,603 4,191 4,080 4,171 4,155
Total Preferred & Common Equity
4,215 4,493 4,843 4,770 4,496 4,310 4,603 4,191 4,080 4,171 4,155
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
4,215 4,493 4,843 4,770 4,496 4,310 4,603 4,191 4,080 4,171 4,155
Common Stock
410 390 439 453 462 434 454 420 471 511 536
Retained Earnings
3,887 4,188 4,489 4,326 4,091 3,904 4,159 3,762 3,616 3,676 3,714
Accumulated Other Comprehensive Income / (Loss)
-82 -85 -85 -9.00 -57 -28 -10 9.00 -7.00 -16 -95

Annual Metrics And Ratios for Molina Healthcare

This table displays calculated financial ratios and metrics derived from Molina Healthcare's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
46.66% 25.42% 11.82% -4.99% -10.91% 15.41% 42.98% 15.13% 6.56% 19.31% 11.75%
EBITDA Growth
54.11% -4.60% -154.72% 536.97% -7.49% 0.26% -2.17% 19.80% 29.28% 8.54% -48.44%
EBIT Growth
102.08% -21.13% -261.44% 325.51% -4.94% 0.38% -6.40% 17.89% 34.10% 8.52% -54.25%
NOPAT Growth
93.90% -54.84% -600.52% 306.03% -1.10% -4.63% 1.76% 13.77% 34.13% 8.05% -50.59%
Net Income Growth
130.65% -63.64% -1,084.62% 238.09% 4.24% -8.68% -2.08% 20.18% 37.75% 8.07% -59.97%
EPS Growth
100.00% -64.34% -1,085.87% 216.98% 8.11% -2.09% 0.18% 20.44% 38.52% 8.79% -56.32%
Operating Cash Flow Growth
6.13% -40.18% 19.47% -139.05% 238.22% 337.33% 11.64% -63.52% 115.01% -61.25% -183.07%
Free Cash Flow Firm Growth
-41.76% -17.48% 78.69% -123.87% 424.09% 157.82% 32.34% -77.18% 260.37% -90.43% -444.38%
Invested Capital Growth
-40.63% -29.82% -78.89% 38.92% 15.90% -51.72% -57.00% 14.63% -14.21% 37.64% 61.17%
Revenue Q/Q Growth
8.16% 3.87% 2.13% -1.49% -2.26% 5.21% 8.49% 2.61% 2.48% 3.70% 1.97%
EBITDA Q/Q Growth
-3.52% -11.58% -28,500.00% 72.36% -3.37% -10.64% 8.27% -5.20% 13.47% 3.78% -35.87%
EBIT Q/Q Growth
-4.79% -21.13% -127.65% 102.18% -3.46% -11.64% 8.15% -6.83% 15.49% 3.90% -40.97%
NOPAT Q/Q Growth
0.15% -54.72% -90.07% 137.41% -3.70% -13.83% 11.81% -7.25% 15.83% 3.23% -38.44%
Net Income Q/Q Growth
-2.44% -59.69% -72.39% 189.75% -4.29% -16.60% 11.69% -5.60% 17.19% 3.06% -46.55%
EPS Q/Q Growth
-6.52% -60.00% -71.78% 263.36% -3.21% -15.82% 11.72% -5.44% 17.02% 3.76% -44.73%
Operating Cash Flow Q/Q Growth
0.02% -21.01% -19.36% 8.72% 57.82% 198.90% -24.88% -51.14% -22.34% 261.80% -16.05%
Free Cash Flow Firm Q/Q Growth
-39.21% 55.31% -18.01% 60.64% -5.58% 189.08% -22.13% -60.53% -22.27% 158.76% -3.22%
Invested Capital Q/Q Growth
16.33% -1.90% -2.21% 8.86% 10.49% -86.02% -10.27% 10.46% 23.36% 22.78% 19.28%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
98.64% 97.27% 11.66% 17.94% 17.37% 18.55% 14.64% 15.01% 15.86% 15.31% 13.07%
EBITDA Margin
3.84% 2.92% -1.43% 6.57% 6.82% 5.93% 4.05% 4.22% 5.12% 4.66% 2.15%
Operating Margin
2.73% 1.72% -2.79% 5.99% 6.20% 5.55% 3.67% 3.67% 4.62% 4.20% 1.72%
EBIT Margin
2.74% 1.72% -2.48% 5.90% 6.29% 5.47% 3.58% 3.67% 4.62% 4.20% 1.72%
Profit (Net Income) Margin
1.01% 0.29% -2.58% 3.74% 4.38% 3.47% 2.37% 2.48% 3.20% 2.90% 1.04%
Tax Burden Percent
44.41% 25.37% 83.66% 70.77% 75.82% 70.03% 75.31% 74.51% 74.52% 74.20% 80.14%
Interest Burden Percent
82.99% 66.99% 123.89% 89.68% 91.78% 90.40% 87.94% 90.62% 93.07% 93.09% 75.42%
Effective Tax Rate
55.59% 74.63% 0.00% 29.23% 24.18% 29.97% 24.69% 25.49% 25.48% 25.80% 19.86%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
11.14% 3.24% -34.29% 47.39% 40.87% 33.19% 27.89% 28.32% 30.39% 27.07% 11.02%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
7.05% 4.36% -6.21% 14.26% 15.19% 13.03% 9.15% 9.57% 11.56% 11.19% 5.01%
Return on Assets (ROA)
2.60% 0.74% -6.43% 9.05% 10.57% 8.25% 6.06% 6.46% 8.02% 7.73% 3.03%
Return on Common Equity (ROCE)
11.14% 3.24% -34.29% 47.39% 40.87% 33.19% 27.89% 28.32% 30.39% 27.07% 11.02%
Return on Equity Simple (ROE_SIMPLE)
9.18% 3.15% -38.29% 42.93% 37.60% 32.11% 25.06% 26.72% 25.88% 26.22% 0.00%
Net Operating Profit after Tax (NOPAT)
172 78 -389 800 792 755 768 874 1,172 1,267 626
NOPAT Margin
1.21% 0.44% -1.95% 4.24% 4.70% 3.89% 2.77% 2.73% 3.44% 3.12% 1.38%
Net Nonoperating Expense Percent (NNEP)
-1.31% -0.90% -3.59% -2.67% -1.70% -2.25% -2.25% -1.46% -1.27% -1.29% -2.76%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 17.00% 18.33% 17.07% 7.99%
Cost of Revenue to Revenue
1.36% 2.73% 88.34% 82.06% 82.63% 81.45% 85.36% 84.99% 84.14% 84.69% 86.93%
SG&A Expenses to Revenue
8.08% 7.83% 8.02% 7.38% 7.74% 7.78% 7.67% 7.41% 7.60% 6.99% 6.82%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
95.91% 95.55% 14.45% 11.95% 11.17% 13.00% 10.97% 11.34% 11.24% 11.11% 11.35%
Earnings before Interest and Taxes (EBIT)
388 306 -494 1,114 1,059 1,063 995 1,173 1,573 1,707 781
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
544 519 -284 1,241 1,148 1,151 1,126 1,349 1,744 1,893 976
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.17 1.87 3.27 4.40 4.34 6.02 7.06 6.51 5.00 3.70 2.19
Price to Tangible Book Value (P/TBV)
3.68 3.47 4.05 4.98 4.76 10.92 13.48 12.25 7.62 6.51 4.76
Price to Revenue (P/Rev)
0.24 0.17 0.22 0.38 0.51 0.65 0.67 0.60 0.62 0.41 0.20
Price to Earnings (P/E)
23.58 59.29 0.00 10.26 11.54 18.74 28.19 24.35 19.31 14.12 18.90
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.24% 1.69% 0.00% 9.75% 8.66% 5.34% 3.55% 4.11% 5.18% 7.08% 5.29%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.05 0.00 0.03 0.22 0.31 0.44 0.46 0.43 0.41 0.25 0.09
Enterprise Value to EBITDA (EV/EBITDA)
1.36 0.08 0.00 3.29 4.59 7.45 11.45 10.17 7.96 5.44 4.23
Enterprise Value to EBIT (EV/EBIT)
1.91 0.13 0.00 3.66 4.97 8.07 12.96 11.69 8.82 6.03 5.29
Enterprise Value to NOPAT (EV/NOPAT)
4.32 0.53 0.00 5.10 6.65 11.36 16.79 15.70 11.84 8.13 6.60
Enterprise Value to Operating Cash Flow (EV/OCF)
0.66 0.06 0.68 0.00 12.14 4.52 6.09 17.75 8.35 15.99 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
1.54 0.10 0.77 0.00 9.58 6.05 6.88 32.05 9.00 69.79 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.03 1.00 1.62 0.89 0.63 1.01 0.83 0.73 0.52 0.65 0.93
Long-Term Debt to Equity
0.75 0.71 1.13 0.74 0.63 1.01 0.83 0.73 0.52 0.65 0.93
Financial Leverage
-1.72 -1.77 -2.30 -2.35 -1.78 -1.79 -2.06 -2.01 -1.78 -1.55 -1.30
Leverage Ratio
4.29 4.37 5.33 5.24 3.87 4.02 4.60 4.38 3.79 3.50 3.64
Compound Leverage Factor
3.56 2.93 6.61 4.70 3.55 3.64 4.05 3.97 3.53 3.26 2.75
Debt to Total Capital
50.82% 49.94% 61.87% 46.96% 38.69% 50.37% 45.24% 42.33% 34.09% 39.40% 48.07%
Short-Term Debt to Total Capital
14.18% 14.33% 18.63% 7.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
36.64% 35.61% 43.24% 39.19% 38.69% 50.37% 45.24% 42.33% 34.09% 39.40% 48.07%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
49.18% 50.06% 38.13% 53.04% 61.31% 49.63% 54.76% 57.67% 65.91% 60.60% 51.93%
Debt to EBITDA
2.96 3.17 -7.64 1.17 1.08 1.85 1.93 1.61 1.25 1.54 3.86
Net Debt to EBITDA
-4.83 -5.86 13.48 -2.55 -2.82 -3.51 -5.04 -4.13 -4.12 -3.35 -4.91
Long-Term Debt to EBITDA
2.13 2.26 -5.34 0.98 1.08 1.85 1.93 1.61 1.25 1.54 3.86
Debt to NOPAT
9.36 21.19 -5.58 1.82 1.56 2.82 2.83 2.49 1.86 2.31 6.02
Net Debt to NOPAT
-15.30 -39.19 9.86 -3.96 -4.09 -5.35 -7.39 -6.37 -6.13 -5.01 -7.65
Long-Term Debt to NOPAT
6.75 15.11 -3.90 1.52 1.56 2.82 2.83 2.49 1.86 2.31 6.02
Altman Z-Score
3.19 3.22 2.85 4.51 4.90 4.06 4.28 4.78 4.54 4.60 4.26
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.39 1.31 1.35 1.52 1.83 1.59 1.43 1.47 1.54 1.62 1.69
Quick Ratio
1.24 1.21 1.18 1.37 1.78 1.55 1.39 1.43 1.50 1.56 1.60
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
482 398 711 -170 550 1,417 1,875 428 1,542 148 -508
Operating Cash Flow to CapEx
852.27% 382.39% 934.88% -1,046.67% 761.40% 2,564.86% 2,751.95% 849.45% 1,978.57% 644.00% -529.70%
Free Cash Flow to Firm to Interest Expense
7.30 3.94 6.02 -1.47 6.32 13.89 15.63 3.89 14.15 1.25 -2.65
Operating Cash Flow to Interest Expense
17.05 6.66 6.81 -2.73 4.99 18.61 17.66 7.03 15.25 5.46 -2.79
Operating Cash Flow Less CapEx to Interest Expense
15.05 4.92 6.08 -2.99 4.33 17.88 17.02 6.20 14.48 4.61 -3.31
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
2.58 2.54 2.50 2.42 2.41 2.38 2.55 2.61 2.50 2.66 2.91
Accounts Receivable Turnover
23.77 22.64 21.55 17.16 12.30 12.62 14.43 14.28 12.61 12.70 13.30
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
38.63 41.99 49.96 64.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.64 1.30 46.78 41.01 31.18 27.68 31.97 31.40 26.78 26.66 32.58
Days Sales Outstanding (DSO)
15.36 16.12 16.93 21.26 29.67 28.92 25.29 25.57 28.96 28.75 27.45
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
571.14 281.09 7.80 8.90 11.71 13.19 11.42 11.62 13.63 13.69 11.20
Cash Conversion Cycle (CCC)
-555.78 -264.96 9.13 12.36 17.96 15.74 13.88 13.94 15.33 15.05 16.24
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1,073 -1,393 -2,492 -1,522 -1,280 -1,942 -3,049 -2,603 -2,973 -1,854 -720
Invested Capital Turnover
-15.44 -14.42 -10.24 -9.41 -12.01 -12.06 -11.13 -11.31 -12.22 -16.84 -35.30
Increase / (Decrease) in Invested Capital
-310 -320 -1,099 970 242 -662 -1,107 446 -370 1,119 1,134
Enterprise Value (EV)
742 41 549 4,082 5,268 8,574 12,897 13,718 13,876 10,298 4,131
Market Capitalization
3,372 3,083 4,378 7,251 8,508 12,612 18,576 19,285 21,064 16,648 8,920
Book Value per Share
$27.76 $29.02 $23.42 $26.40 $31.26 $35.35 $45.03 $50.75 $72.30 $78.60 $79.16
Tangible Book Value per Share
$16.33 $15.65 $18.95 $23.35 $28.52 $19.48 $23.60 $26.95 $47.44 $44.72 $36.46
Total Capital
3,166 3,294 3,506 3,105 3,197 4,223 4,803 5,140 6,395 7,419 7,835
Total Debt
1,609 1,645 2,169 1,458 1,237 2,127 2,173 2,176 2,180 2,923 3,766
Total Long-Term Debt
1,160 1,173 1,516 1,217 1,237 2,127 2,173 2,176 2,180 2,923 3,766
Net Debt
-2,630 -3,042 -3,829 -3,169 -3,240 -4,038 -5,679 -5,567 -7,188 -6,350 -4,789
Capital Expenditures (CapEx)
132 176 86 30 57 74 77 91 84 100 101
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2,197 -2,687 -3,272 -2,050 -1,700 -3,118 -4,623 -4,276 -4,733 -4,110 -3,184
Debt-free Net Working Capital (DFNWC)
1,933 1,890 2,607 2,457 2,698 2,911 3,017 3,229 4,374 4,877 5,072
Net Working Capital (NWC)
1,484 1,418 1,954 2,216 2,698 2,911 3,017 3,229 4,374 4,877 5,072
Net Nonoperating Expense (NNE)
29 26 124 93 55 82 109 82 81 88 154
Net Nonoperating Obligations (NNO)
-2,630 -3,042 -3,829 -3,169 -3,240 -4,038 -5,679 -5,567 -7,188 -6,350 -4,789
Total Depreciation and Amortization (D&A)
156 213 210 127 89 88 131 176 171 186 195
Debt-free, Cash-free Net Working Capital to Revenue
-15.50% -15.11% -16.46% -10.85% -10.10% -16.05% -16.65% -13.37% -13.89% -10.11% -7.01%
Debt-free Net Working Capital to Revenue
13.63% 10.63% 13.11% 13.01% 16.03% 14.99% 10.86% 10.10% 12.84% 12.00% 11.17%
Net Working Capital to Revenue
10.47% 7.97% 9.83% 11.73% 16.03% 14.99% 10.86% 10.10% 12.84% 12.00% 11.17%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$2.75 $0.93 ($9.07) $11.57 $11.85 $11.40 $11.40 $13.72 $18.91 $20.52 $8.93
Adjusted Weighted Average Basic Shares Outstanding
52M 55M 56M 61M 62.20M 59M 57.80M 57.80M 57.70M 57.40M 52.80M
Adjusted Diluted Earnings per Share
$2.58 $0.92 ($9.07) $10.61 $11.47 $11.23 $11.25 $13.55 $18.77 $20.42 $8.92
Adjusted Weighted Average Diluted Shares Outstanding
56M 56M 56M 67M 64.20M 59.90M 58.60M 58.50M 58.10M 57.70M 52.90M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
56.20M 56.75M 59.73M 62.46M 60.80M 58M 58.40M 57.90M 58.40M 55.50M 51.50M
Normalized Net Operating Profit after Tax (NOPAT)
271 214 104 800 792 755 768 1,029 1,172 1,267 626
Normalized NOPAT Margin
1.91% 1.20% 0.52% 4.24% 4.70% 3.89% 2.77% 3.22% 3.44% 3.12% 1.38%
Pre Tax Income Margin
2.27% 1.15% -3.08% 5.29% 5.78% 4.95% 3.15% 3.32% 4.30% 3.91% 1.30%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
5.88 3.03 -4.19 9.69 12.17 10.42 8.29 10.66 14.43 14.47 4.07
NOPAT to Interest Expense
2.60 0.77 -3.29 6.96 9.10 7.40 6.40 7.95 10.75 10.73 3.26
EBIT Less CapEx to Interest Expense
3.88 1.29 -4.92 9.43 11.52 9.70 7.65 9.84 13.66 13.62 3.54
NOPAT Less CapEx to Interest Expense
0.60 -0.97 -4.02 6.70 8.44 6.68 5.76 7.12 9.98 9.89 2.73
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 77.65% 76.12% 94.50% 19.42% 50.51% 0.00% 84.82% 211.86%

Quarterly Metrics And Ratios for Molina Healthcare

This table displays calculated financial ratios and metrics derived from Molina Healthcare's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 51,500,000.00 52,100,000.00 52,200,000.00
DEI Adjusted Shares Outstanding
- - - - - - - - 51,500,000.00 52,100,000.00 52,200,000.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.27 1.15 0.73
Growth Metrics
- - - - - - - - - - -
Revenue Growth
21.87% 18.65% 20.96% 16.04% 12.24% 15.66% 11.00% 8.34% -3.15% -4.84% -3.44%
EBITDA Growth
-5.61% -1.03% 28.18% 19.22% 2.12% -10.21% -64.59% -127.57% -74.64% -57.08% -20.88%
EBIT Growth
-6.37% -2.03% 30.08% 20.25% 1.64% -14.06% -70.66% -142.63% -80.83% -61.13% -22.63%
NOPAT Growth
-6.05% -2.22% 31.20% 16.72% 2.95% -9.04% -64.62% -141.14% -87.89% -67.33% -38.21%
Net Income Growth
-6.23% -2.59% 33.06% 16.20% -1.00% -15.28% -75.77% -163.75% -95.30% -76.47% -51.90%
EPS Growth
-6.34% -3.36% 34.20% 20.05% 5.42% -8.12% -73.27% -162.98% -95.05% -74.95% -51.66%
Operating Cash Flow Growth
-76.64% -144.97% -8.01% 67.54% -11.22% -37.90% -114.32% -33.04% 469.47% 2.65% -27.20%
Free Cash Flow Firm Growth
-167.26% -303.14% -191.39% -239.12% -60.59% 45.84% -22.61% -47.91% 107.41% 149.33% 113.13%
Invested Capital Growth
19.61% 40.08% 38.10% 37.64% 31.84% 42.31% 62.85% 61.17% 0.29% -14.80% -11.88%
Revenue Q/Q Growth
9.76% -0.51% 4.66% 1.54% 6.17% 2.51% 0.44% -0.89% -5.09% 0.72% 1.91%
EBITDA Q/Q Growth
31.20% 1.91% 7.08% -16.73% 12.38% -10.40% -57.77% -164.84% 203.39% 51.64% -22.16%
EBIT Q/Q Growth
34.81% 1.88% 7.60% -18.63% 13.95% -13.86% -63.27% -218.25% 151.23% 74.70% -26.90%
NOPAT Q/Q Growth
36.07% 0.12% 8.03% -20.69% 20.02% -11.54% -57.98% -192.20% 135.33% 138.60% -20.51%
Net Income Q/Q Growth
39.35% 0.00% 8.31% -23.01% 18.73% -14.43% -69.02% -302.53% 108.75% 328.57% -36.67%
EPS Q/Q Growth
40.11% 0.00% 9.28% -21.59% 23.02% -12.84% -68.21% -284.77% 109.68% 340.74% -38.66%
Operating Cash Flow Q/Q Growth
131.01% -202.34% 498.63% -125.66% 184.82% -258.95% 58.61% -138.40% 463.09% -127.17% 45.92%
Free Cash Flow Firm Q/Q Growth
-148.60% -232.36% -15.44% 25.40% 43.90% -12.09% -161.34% 10.00% 102.81% 645.97% -30.43%
Invested Capital Q/Q Growth
15.07% 22.97% -23.44% 22.78% 7.17% 34.81% 20.50% 19.28% -138.33% 24.94% 22.52%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
15.28% 15.30% 16.41% 14.25% 14.96% 13.98% 12.49% 10.89% 14.13% 13.19% 12.30%
EBITDA Margin
4.74% 4.86% 4.97% 4.08% 4.32% 3.77% 1.59% -1.04% 1.13% 1.70% 1.30%
Operating Margin
4.29% 4.39% 4.52% 3.62% 3.88% 3.26% 1.19% -1.42% 0.77% 1.33% 0.96%
EBIT Margin
4.29% 4.39% 4.52% 3.62% 3.88% 3.26% 1.19% -1.42% 0.77% 1.33% 0.96%
Profit (Net Income) Margin
3.03% 3.05% 3.15% 2.39% 2.67% 2.23% 0.69% -1.41% 0.13% 0.55% 0.34%
Tax Burden Percent
75.44% 74.14% 74.43% 72.54% 76.41% 78.46% 89.77% 74.77% 48.28% 65.93% 71.70%
Interest Burden Percent
93.66% 93.55% 93.79% 91.05% 90.07% 87.13% 64.23% 132.10% 34.94% 62.76% 50.00%
Effective Tax Rate
24.56% 25.86% 25.57% 27.46% 23.59% 21.54% 10.23% 0.00% 51.72% 34.07% 28.30%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
27.53% 25.12% 26.45% 27.07% 26.72% 23.93% 19.71% 11.02% 4.48% -0.16% -1.15%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
10.65% 11.39% 11.56% 9.64% 10.20% 9.03% 3.38% -4.15% 2.11% 3.69% 2.69%
Return on Assets (ROA)
7.52% 7.90% 8.07% 6.37% 7.02% 6.17% 1.95% -4.10% 0.36% 1.53% 0.97%
Return on Common Equity (ROCE)
27.53% 25.12% 26.45% 27.07% 26.72% 23.93% 19.71% 11.02% 4.48% -0.16% -1.15%
Return on Equity Simple (ROE_SIMPLE)
23.84% 21.95% 23.98% 0.00% 27.29% 24.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
321 322 348 276 331 293 123 -113 40 96 76
NOPAT Margin
3.24% 3.26% 3.36% 2.63% 2.97% 2.56% 1.07% -1.00% 0.37% 0.88% 0.69%
Net Nonoperating Expense Percent (NNEP)
-0.30% -0.30% -0.29% -0.36% -0.50% -0.60% -0.72% -0.84% -0.44% -0.64% -0.74%
Return On Investment Capital (ROIC_SIMPLE)
- - - 3.72% 4.20% 3.67% 1.57% -1.45% 0.51% 1.20% 0.96%
Cost of Revenue to Revenue
84.72% 84.70% 83.59% 85.75% 85.04% 86.02% 87.51% 89.11% 85.87% 86.81% 87.70%
SG&A Expenses to Revenue
7.54% 7.43% 6.54% 6.51% 7.17% 6.44% 6.35% 7.34% 7.22% 6.66% 6.41%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
10.99% 10.91% 11.91% 10.62% 11.08% 10.72% 11.29% 12.32% 13.37% 11.85% 11.34%
Earnings before Interest and Taxes (EBIT)
426 434 467 380 433 373 137 -162 83 145 106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
471 480 514 428 481 431 182 -118 122 185 144
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.33 3.60 4.23 3.70 4.24 3.51 2.47 2.19 1.68 2.86 2.38
Price to Tangible Book Value (P/TBV)
9.33 5.95 7.09 6.51 8.56 6.63 5.21 4.76 3.45 5.70 4.74
Price to Revenue (P/Rev)
0.67 0.47 0.52 0.41 0.44 0.37 0.23 0.20 0.15 0.27 0.22
Price to Earnings (P/E)
22.36 16.39 17.65 14.12 15.55 14.29 11.75 18.90 36.52 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.47% 6.10% 5.67% 7.08% 6.43% 7.00% 8.51% 5.29% 2.74% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.47 0.28 0.33 0.25 0.29 0.24 0.12 0.09 0.02 0.15 0.11
Enterprise Value to EBITDA (EV/EBITDA)
9.87 6.22 7.14 5.44 6.44 5.62 3.47 4.23 1.73 17.40 14.17
Enterprise Value to EBIT (EV/EBIT)
10.97 6.93 7.92 6.03 7.15 6.30 4.00 5.29 2.48 31.80 27.43
Enterprise Value to NOPAT (EV/NOPAT)
14.70 9.29 10.61 8.13 9.60 8.36 5.20 6.60 3.01 45.43 39.19
Enterprise Value to Operating Cash Flow (EV/OCF)
17.64 41.87 73.15 15.99 19.76 19.41 0.00 0.00 2.99 17.69 14.25
Enterprise Value to Free Cash Flow (EV/FCFF)
31.62 0.00 0.00 69.79 25.97 24.63 0.00 0.00 3.05 20.96 20.84
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.49 0.45 0.49 0.65 0.83 0.73 0.87 0.93 0.92 0.90 0.91
Long-Term Debt to Equity
0.49 0.45 0.49 0.65 0.83 0.73 0.87 0.93 0.92 0.90 0.91
Financial Leverage
-1.73 -1.61 -1.73 -1.55 -1.48 -1.32 -1.37 -1.30 -1.41 -1.27 -1.23
Leverage Ratio
3.71 3.41 3.54 3.50 3.62 3.32 3.51 3.64 3.91 3.67 3.76
Compound Leverage Factor
3.48 3.19 3.32 3.19 3.26 2.90 2.25 4.81 1.37 2.30 1.88
Debt to Total Capital
32.67% 31.05% 32.84% 39.40% 45.33% 42.30% 46.65% 48.07% 48.01% 47.47% 47.58%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
32.67% 31.05% 32.84% 39.40% 45.33% 42.30% 46.65% 48.07% 48.01% 47.47% 47.58%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
67.33% 68.95% 67.16% 60.60% 54.67% 57.70% 53.35% 51.93% 51.99% 52.53% 52.42%
Debt to EBITDA
1.27 1.27 1.28 1.54 1.88 1.82 2.41 3.86 6.11 10.16 11.32
Net Debt to EBITDA
-4.09 -3.97 -3.93 -3.35 -3.17 -3.09 -3.34 -4.91 -9.39 -14.71 -15.47
Long-Term Debt to EBITDA
1.27 1.27 1.28 1.54 1.88 1.82 2.41 3.86 6.11 10.16 11.32
Debt to NOPAT
1.89 1.91 1.90 2.31 2.80 2.71 3.60 6.02 10.60 26.52 31.32
Net Debt to NOPAT
-6.09 -5.93 -5.84 -5.01 -4.73 -4.59 -5.00 -7.65 -16.31 -38.42 -42.80
Long-Term Debt to NOPAT
1.89 1.91 1.90 2.31 2.80 2.71 3.60 6.02 10.60 26.52 31.32
Altman Z-Score
4.41 4.34 4.42 4.32 4.26 4.34 4.13 4.07 3.79 4.13 4.08
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.49 1.57 1.55 1.62 1.63 1.66 1.68 1.69 1.63 1.68 1.69
Quick Ratio
1.44 1.52 1.50 1.56 1.57 1.61 1.60 1.60 1.55 1.61 1.61
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-295 -979 -1,130 -843 -473 -530 -1,386 -1,247 35 262 182
Operating Cash Flow to CapEx
792.59% -811.11% 2,494.29% -2,036.36% 863.64% -719.05% -328.95% 0.00% 4,007.41% -980.00% -429.73%
Free Cash Flow to Firm to Interest Expense
-10.91 -34.97 -38.98 -24.80 -11.00 -11.05 -28.29 -23.99 0.65 4.84 3.43
Operating Cash Flow to Interest Expense
7.93 -7.82 30.10 -6.59 4.42 -6.29 -2.55 -5.73 20.04 -5.44 -3.00
Operating Cash Flow Less CapEx to Interest Expense
6.93 -8.79 28.90 -6.91 3.91 -7.17 -3.33 -5.71 19.54 -6.00 -3.70
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
2.48 2.59 2.56 2.66 2.62 2.77 2.83 2.91 2.75 2.76 2.82
Accounts Receivable Turnover
12.18 13.32 13.71 12.70 12.24 12.24 13.15 13.30 13.04 12.11 12.84
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
31.79 34.47 28.53 26.66 31.79 35.43 32.80 32.58 34.46 34.54 33.43
Days Sales Outstanding (DSO)
29.96 27.40 26.63 28.75 29.82 29.83 27.75 27.45 27.98 30.13 28.43
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
11.48 10.59 12.79 13.69 11.48 10.30 11.13 11.20 10.59 10.57 10.92
Cash Conversion Cycle (CCC)
18.48 16.81 13.83 15.05 18.34 19.53 16.62 16.24 17.39 19.56 17.51
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2,525 -1,945 -2,401 -1,854 -1,721 -1,122 -892 -720 -1,716 -1,288 -998
Invested Capital Turnover
-12.66 -14.41 -12.48 -16.84 -19.72 -28.31 -27.06 -35.30 -26.23 -36.95 -46.70
Increase / (Decrease) in Invested Capital
616 1,301 1,478 1,119 804 823 1,509 1,134 5.00 -166 -106
Enterprise Value (EV)
16,933 10,634 13,020 10,298 12,250 10,421 5,289 4,131 1,069 6,456 4,718
Market Capitalization
23,951 17,422 20,191 16,648 18,281 16,146 10,372 8,920 6,865 11,915 9,871
Book Value per Share
$76.67 $82.65 $81.40 $78.60 $77.66 $84.93 $77.32 $79.16 $79.22 $80.06 $79.60
Tangible Book Value per Share
$43.79 $50.00 $48.58 $44.72 $38.47 $44.93 $36.70 $36.46 $38.60 $40.10 $39.89
Total Capital
6,673 7,024 7,102 7,419 7,884 7,978 7,855 7,835 7,847 7,940 7,926
Total Debt
2,180 2,181 2,332 2,923 3,574 3,375 3,664 3,766 3,767 3,769 3,771
Total Long-Term Debt
2,180 2,181 2,332 2,923 3,574 3,375 3,664 3,766 3,767 3,769 3,771
Net Debt
-7,018 -6,788 -7,171 -6,350 -6,031 -5,725 -5,083 -4,789 -5,796 -5,459 -5,153
Capital Expenditures (CapEx)
27 27 35 11 22 42 38 -1.00 27 30 37
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4,783 -4,206 -4,670 -4,110 -4,192 -3,573 -3,376 -3,184 -4,113 -3,687 -3,459
Debt-free Net Working Capital (DFNWC)
4,154 4,495 4,544 4,877 5,102 5,236 5,071 5,072 5,138 5,228 5,120
Net Working Capital (NWC)
4,154 4,495 4,544 4,877 5,102 5,236 5,071 5,072 5,138 5,228 5,120
Net Nonoperating Expense (NNE)
20 21 22 25 33 38 44 47 26 36 38
Net Nonoperating Obligations (NNO)
-7,018 -6,788 -7,171 -6,350 -6,031 -5,725 -5,083 -4,789 -5,796 -5,459 -5,153
Total Depreciation and Amortization (D&A)
45 46 47 48 48 58 45 44 39 40 38
Debt-free, Cash-free Net Working Capital to Revenue
-13.34% -11.24% -11.91% -10.11% -10.01% -8.23% -7.58% -7.01% -9.12% -8.28% -7.84%
Debt-free Net Working Capital to Revenue
11.59% 12.02% 11.59% 12.00% 12.19% 12.06% 11.38% 11.17% 11.40% 11.74% 11.60%
Net Working Capital to Revenue
11.59% 12.02% 11.59% 12.00% 12.19% 12.06% 11.38% 11.17% 11.40% 11.74% 11.60%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.21 $5.18 $5.67 $4.46 $5.47 $4.75 $1.51 ($2.80) $0.27 $1.19 $0.74
Adjusted Weighted Average Basic Shares Outstanding
58.60M 58.60M 57.20M 57.40M 54.20M 54.20M 51.40M 52.80M 52.10M 52.20M 52.20M
Adjusted Diluted Earnings per Share
$5.17 $5.17 $5.65 $4.43 $5.45 $4.75 $1.51 ($2.79) $0.27 $1.19 $0.73
Adjusted Weighted Average Diluted Shares Outstanding
58.60M 58.60M 57.20M 57.70M 54.20M 54.20M 51.40M 52.90M 52.10M 52.20M 52.20M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
58.60M 58.60M 57.20M 55.50M 54.20M 54.20M 51.40M 51.50M 52.10M 52.20M 52.20M
Normalized Net Operating Profit after Tax (NOPAT)
321 322 348 276 331 293 123 -113 123 96 76
Normalized NOPAT Margin
3.24% 3.26% 3.36% 2.63% 2.97% 2.56% 1.07% -1.00% 1.14% 0.88% 0.69%
Pre Tax Income Margin
4.02% 4.11% 4.24% 3.30% 3.50% 2.84% 0.77% -1.88% 0.27% 0.84% 0.48%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
15.78 15.50 16.10 11.18 10.07 7.77 2.80 -3.12 1.54 2.69 2.00
NOPAT to Interest Expense
11.90 11.49 11.99 8.11 7.69 6.10 2.51 -2.18 0.74 1.77 1.43
EBIT Less CapEx to Interest Expense
14.78 14.54 14.90 10.85 9.56 6.90 2.02 -3.10 1.04 2.13 1.30
NOPAT Less CapEx to Interest Expense
10.90 10.53 10.78 7.78 7.18 5.22 1.73 -2.16 0.24 1.21 0.74
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 43.71% 84.82% 127.55% 132.74% 169.88% 211.86% 265.96% -7,142.86% 0.00%

Financials Breakdown Chart

Key Financial Trends

Molina Healthcare’s revenue has continued to expand, but profitability and cash-flow trends have weakened materially. Quarterly operating revenue increased from $8.15 billion in Q1 2023 to $10.87 billion in Q2 2026, a gain of roughly 33%. However, operating income declined from $455 million to $145 million over the same period, reducing the operating margin from approximately 5.6% to 1.3%.

The deterioration has been especially visible in the most recent year. Q2 2026 net income was $60 million, or $1.19 per diluted share, compared with $255 million, or $4.75 per diluted share, in Q2 2025. Net income has recovered from the $160 million loss reported in Q4 2025, but remains well below the profit levels recorded during 2023 and most of 2024.

  • Revenue growth remains a major strength. Q2 2026 revenue of $10.87 billion was approximately 33% above Q1 2023 revenue of $8.15 billion.
  • Molina retains substantial liquidity. At June 30, 2026, cash and equivalents totaled $4.99 billion, while short-term investments totaled $3.93 billion. These liquid assets were more than enough to cover current liabilities of $7.70 billion.
  • The company has reduced its share count over the longer term. Weighted average diluted shares declined from 58.3 million in Q1 2023 to 52.2 million in Q2 2026, which can support per-share results when earnings improve.
  • Goodwill and total assets have expanded since 2023, with goodwill rising from $1.37 billion in Q1 2023 to $2.08 billion in Q2 2026. This suggests Molina has continued investing in growth, although the quality of that growth requires monitoring.
  • Q2 2026 operating cash flow was negative $294 million, but cash generation has been highly volatile rather than consistently negative. Q1 2026 produced $1.08 billion of operating cash flow, compared with $190 million in Q1 2025.
  • Investment activity largely reflects portfolio management. In Q2 2026, Molina purchased and sold approximately $377 million of investments, resulting in only a $30 million net investing cash outflow, primarily from capital expenditures.
  • Margins have compressed significantly. Q2 gross profit fell to $1.43 billion from $1.60 billion in Q2 2025, while the gross margin declined from approximately 14.0% to 13.2% as operating costs rose faster than revenue.
  • Earnings remain well below prior-year levels. Q2 2026 net income dropped approximately 76% year over year, and diluted EPS fell from $4.75 to $1.19. The decline followed weaker operating income and continued pressure from other operating expenses.
  • Operating cash flow has frequently failed to cover the company’s cash needs. Molina reported negative operating cash flow in Q2 2024, Q2 2025, Q3 2025, Q4 2025 and Q2 2026. The Q2 2026 shortfall contributed to a $328 million decline in cash and equivalents.
  • Leverage has increased from 2023 levels. Long-term debt rose from $2.18 billion in Q1 2023 to $3.77 billion in Q2 2026, while total liabilities reached $11.83 billion. Although liquidity remains strong, higher debt could limit flexibility if profitability stays depressed.

Overall, the statements show a larger company with strong liquidity and long-term revenue growth, but also a sharp decline in margins, earnings and the reliability of operating cash flow. Investors should focus on whether Molina can stabilize medical and other operating costs, restore sustained positive operating cash flow and improve profitability without relying on additional debt.

11/16/26 11:06 AM ETAI Generated. May Contain Errors.

Molina Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Molina Healthcare's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Molina Healthcare's net income appears to be on an upward trend, with a most recent value of $472 million in 2025, rising from $143 million in 2015. The previous period was $1.18 billion in 2024. View Molina Healthcare's forecast to see where analysts expect Molina Healthcare to go next.

Molina Healthcare's total operating income in 2025 was $781 million, based on the following breakdown:
  • Total Gross Profit: $5.94 billion
  • Total Operating Expenses: $5.16 billion

Over the last 10 years, Molina Healthcare's total revenue changed from $14.18 billion in 2015 to $45.43 billion in 2025, a change of 220.4%.

In the past 11 quarters, Molina Healthcare's cash and equivalents has ranged from $4.22 billion in Q3 2025 to $5.31 billion in Q1 2026, and is currently $4.48 billion as of their latest financial filing in Q3 2026.

Molina Healthcare had total debt of $3.77 billion at the end of 2025, a 28.8% increase from 2024, and a 134.1% increase since 2015.

Over the last 10 years, Molina Healthcare's book value per share changed from 27.76 in 2015 to 79.16 in 2025, a change of 185.1%.



Financial statements for NYSE:MOH last updated on 10/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners